A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• In-frame insertions in HER2 exon 20 are common in non-small cell lung cancer (NSCLC).
• Existing EGFR/HER2 tyrosine kinase inhibitors (TKIs) have limited efficacy and side effects in NSCLC due to wild-type EGFR inhibition.
• HER2 amplification also contributes to NSCLC progression.

Purpose of the Study:

• To develop and characterize a novel HER2-selective covalent TKI targeting common HER2 mutations in NSCLC.
• To investigate the mechanism of action and anti-tumoral activity of the new TKI, JBJ-08-178-01.
• To evaluate the potential of JBJ-08-178-01 for improved efficacy and tolerance in NSCLC patients.

Main Methods:

• Development of a HER2-selective covalent TKI, JBJ-08-178-01.
• Biochemical assays to assess selectivity against wild-type EGFR.
• Crystal structure determination of HER2 complexed with JBJ-08-178-01.
• In vitro and in vivo studies in cancer models with HER2 mutations or amplification.
• Analysis of HER2 protein degradation pathways.

Main Results:

• JBJ-08-178-01 demonstrated potent inhibition of HER2 activating mutations, including exon 20 insertions and amplification.
• The TKI exhibited strong selectivity for HER2 mutants over wild-type EGFR.
• Structural analysis suggested a key interaction at Ser783 contributing to HER2 selectivity.
• JBJ-08-178-01 showed significant anti-tumoral activity in preclinical models.
• The compound promoted proteasomal degradation of HER2, reducing total receptor levels.

Conclusions:

• JBJ-08-178-01 is a novel, HER2-selective covalent TKI with potent anti-tumoral activity against HER2-mutant or amplified NSCLC.
• Its dual mechanism of inhibiting kinase activity and promoting receptor degradation offers a promising therapeutic strategy.
• This dual action may lead to enhanced efficacy and better tolerability for NSCLC patients with specific HER2 alterations.